Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined ...

Approximately 150 subjects will be enrolled, receiving either the therapy or a placebo daily for a 52-week treatment period.

In the NEULARK trial, patients with early-stage LRRK2-driven Parkinson's disease will receive Neuron23's NEU-411 or a placebo.

LRRK2 inhibitors may be key to combating parkinson's disease Date: June 10, 2014 Source: University of Alabama at Birmingham Summary: An enzyme closely associated with genetic forms of Parkinson ...

This study shows that Parkinson's disease–associated mutant forms of leucine-rich repeat kinase 2 (LRRK2) impair chaperone-mediated autophagy in neurons, thereby reducing degradation of α ...

A large longitudinal study found that pesticide exposure and caffeinated soda intake were linked to more severe motor ...

Mutations in LRRK2 account for up to 10 percent of familial PD cases. In addition, the concentration of this protein is elevated in many cases of sporadic disease, hinting at a broad role in pathology ...

The LRRK2 G2019S mutation significantly enhances the phosphorylation of ERM proteins and increases the number of phospho-ERM-positive and F-actin-enriched filopodia.

The LRRK2 G2019S variant. Only 10 percent of Parkinson’s disease cases have a known genetic cause; the remaining 90 percent have idiopathic Parkinson’s disease, where the cause is unknown.

LRRK2: a key therapeutic target for Parkinson's disease. Known as a kinase, LRRK2 is a type of enzyme that adds phosphate chemical tags to other proteins, influencing their function.

More information: Chen, C. et al, LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons, Molecular Psychiatry (2025). DOI: 10.1038/s41380-025-03030-z Provided ...